Hypertens1ve action was observed in conscious rats injected intraventricularly with glandular kallikrein (EC 3.4.21.35) in a dose-dependent manner (4-16 KU), which was associated with the enhancement of brain kinin level. Concurrently administered aprotinin, a kallikrein inhibitor, led to an inhibition of these effects of kallikrein. These results suggest that the central hypertensive action of kallikrein is mediated via the kinin liberated from a kininogen in the brain.
